DRKS00023454招募中未知
Evaluation of the digital health application MAWENDO
Mawendo GmbH0 个研究点目标入组 4,016 人开始时间: 2020年11月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 4,016
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 12 Years 至 one（—）
- 性别
- All
入选标准
- •Above mentionend ICD10 Codes
排除标准
- •1. Minority:
- •Children under 12 years are excluded. Persons under the age of 18 require the consent of a legal representative.
- •2. Health requirements:
- •Illnesses that are outside the selected indication of the training program / physotherapy can pose a risk to participation in the services provided by Mawendo or physiotherapy. These are considered exclusion criteria if they are classified as questionable for the physical exercises of the training programs or physiotherapy. A medical examination is therefore necessary before starting training or physiotherapy. In particular, these are:
- •a) Previous operations in the period up to six months before the start of treatment in connection with one of the indications examined.
- •b) Severe or acute diseases of the cardiovascular system (e.g. acute myocardial infarction, acute ischemic heart disease, high blood pressure with cardiac insufficiency, hypertensive crisis)
- •c) Diseases of the lungs or respiratory tract (e.g. pneumonia, pulmonary embolism)
- •d) Tumor diseases (e.g. malignant neoplasms of bone and articular cartilage, malignant neoplasms of internal organs)
- •e) Infections and fever (e.g. rheumatic fever, purulent arthritis, sepsis, bacterial infections)
- •f) Injuries or diseases of the musculoskeletal system outside the indication for the training program
- •g) Bleeding tendencies (history of excessive bleeding or use of anticoagulant medication)
- •h) Mental disorders (e.g. acute psychosis)
- •i) pregnancy
- •Other diseases not listed here may also be unsuitable for a participation in a Mawendo training program or physiotherapy treatment. Before the treatment, the prescribing doctor will therefore clarify whether the physiotherapy or the exercises, as used in the Mawendo training program, can be completed safely. Otherwise there is a contraindication.
- •3. Eyesight:
- •The Mawendo application is not suitable for users with severe visual impairments.
- •4. Pain intensity before starting treatment:
- •Patients who experience either very little or very severe pain at the start of treatment are excluded to avoid bias. The pain
- •level is recorded by the recruiting doctor on a Verbal Numerical Rating Scale (VRNS, value range 0-10, Mohan et al. (2010)) before the study is included. Patients who score = 2 or = 8 on the VNRS will be excluded from the study.
研究者
相似试验
招募中
不适用
Evaluation of the Digital Health Application glucura in the treatment of Diabetes mellitus Type 2.A randomized controlled trial over a period of 6 monthsE11Type 2 diabetes mellitusDRKS00032537Perfood GmbH650
已完成
不适用
Effectiveness of the digital health application sinCephalea in theprophylaxis of migraine days in patients with episodic migrainesover a period of twelve weeksG43.0G43.1Migraine without aura [common migraine]Migraine with aura [classical migraine]DRKS00024657Perfood GmbH842
已完成
4 期
Evaluation of a digital health app for indiciduals with mild to moderate depression.F32.0F32.1F33.0F33.1Mild depressive episodeModerate depressive episodeRecurrent depressive disorder, current episode mildRecurrent depressive disorder, current episode moderateDRKS00030852MindDoc Health GmbH572
尚未招募
不适用
Evaluation of a Digital Health Promotion Resource for Children about Ergonomic Ways of Using Information and Communication Technologies (ICT)Incorrect postureMusculoskeletal - Other muscular and skeletal disordersACTRN12621001038886Curtin University140
已完成
不适用
Pilot Study of a Digital Health Application for Strengthening Self-Management and Adherence to Therapy Guidelines in Patients with Hypertension, Hypertension, and concomitant Chronic Ischemic Heart Disease, and/or Heart FailureI10I25I50Essential (primary) hypertensionChronic ischaemic heart diseaseHeart failureDRKS00026136apprevent GmbH40